HRP20180334T1 - DENDRITIČKE STANICE S MANIPULIRANIM SIGNALNIM PUTEM NFkB - Google Patents
DENDRITIČKE STANICE S MANIPULIRANIM SIGNALNIM PUTEM NFkB Download PDFInfo
- Publication number
- HRP20180334T1 HRP20180334T1 HRP20180334TT HRP20180334T HRP20180334T1 HR P20180334 T1 HRP20180334 T1 HR P20180334T1 HR P20180334T T HRP20180334T T HR P20180334TT HR P20180334 T HRP20180334 T HR P20180334T HR P20180334 T1 HRP20180334 T1 HR P20180334T1
- Authority
- HR
- Croatia
- Prior art keywords
- dcs
- nfκb
- cells
- seq
- mutant
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 claims 22
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 10
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 230000019491 signal transduction Effects 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- 238000001890 transfection Methods 0.000 claims 4
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000005138 cryopreservation Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000008054 signal transmission Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C12N5/064—Immunosuppressive dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Television Systems (AREA)
- Photovoltaic Devices (AREA)
- Stereo-Broadcasting Methods (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (13)
1. Dendritičke stanice (DC-i), čiji signalni put NFκB je manipuliran transfekcijom RNA jednim ili više nukleotidnih sljedova koji kodiraju najmanje jedan mutantni protein za prijenos signala u signalnom putu NFκB, gdje je mutantni protein za prijenos signala u signalnom putu NFκB konstitutivno aktivni IKKα ili IKKβ mutant, naznačene time što
(i) konstitutivno aktivni IKKα mutant sadrži aminokiselinske ostatke 25 do 769 u SEQ ID NO:2; ili
(ii) konstitutivno aktivni IKKβ mutant sadrži aminokiselinske ostatke 18 do 773 u SEQ ID NO:5.
2. DC-i u skladu s patentnim zahtjevom 1, naznačeni time što konstitutivno aktivni mutanti IKKα i IKKβ imaju slijed SEQ ID NO:2 odnosno SEQ ID NO:5, ili imaju RNA slijed SEQ ID NO:3 ili 6.
3. DC-i u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što navedeni DC-i
(i) su zreli DC-i; i/ili
(ii) su DC-i aktivirani NFκB-om koji proizvode IL-12p70; i/ili
(iii) su DC-i aktivirani NFκB-om koji proizvode IL-10; i/ili
(iv) su dodatno opterećeni jednim ili više ciljanih antigena.
4. Postupak proizvodnje DC-a ex vivo, čiji je signalni put NFκB manipuliran, u skladu s patentnim zahtjevima 1 do 3, naznačen time što se sastoji u transfekciji s RNA nezrelih ili zrelih DC-a jednim ili više nukleotidnih sljedova koji kodiraju mutantni protein za prijenos signala u signalnom putu NFκB u skladu s patentnim zahtjevima 1 do 3.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time što se transfekciju s RNA provodi elektroporacijom.
6. Postupak u skladu s patentnim zahtjevom 4 ili 5, naznačen time što se dodatno sastoji u
(i) u slučaju transfekcije s RNA nezrelih DC-a, obradi stimulusom za zriobu; i/ili
(ii) opterećivanju DC-a ciljanim antigenom; i/ili
(iii) kriokonzerviranjem zrelih DC-a.
7. Pripravak, farmaceutski pripravak ili medikament, koji sadrže DC-e u skladu s jednim ili više patentnih zahtjeva 1 do 3, i izborno farmaceutski prihvatljive pomoćne tvari i nosive spojeve, naznačeni time što su po mogućnosti navedeni DC-i autologni DC-i.
8. Upotreba DC-a u skladu s jednim ili više patentnih zahtjeva 1 do 3, naznačena time što su DC-i namijenjeni stimuliranju autolognih CD8+ T-stanica ex vivo.
9. Upotreba u skladu s patentnim zahtjevom 8, naznačena time što su DC-i aktivirani NFκB-om pogodni za pasivni prijenos T-stanica i generiranje klona T-stanica.
10. DC-i u skladu s jednim ili više patentnih zahtjeva 1 do 3, naznačeni time što su namijenjeni upotrebi u liječenju bolesti kod pacijenta.
11. DC-i namijenjeni upotrebi u skladu s patentnim zahtjevom 10, naznačeni time što su DC-i aktivirani NFκB-om pogodni za cijepljenje na bazi DC, za terapijsko cijepljenje protiv raka ili zaraznih bolesti i kao preventivno cjepivo.
12. Postupak ekspanzije T-stanica, koji uključuje stimuliranje autolognih CD8+ T-stanica ex vivo, naznačen time što se sastoji u stimuliranju T-stanice DC-ima u skladu s jednim ili više patentnih zahtjeva 1 do 3.
13. Postupak u skladu s patentnim zahtjevom 12, naznačeni time što su DC-i aktivirani NFκB-om pogodni za T-staničnu ekspanziju T-stanica za pasivni prijenos T-stanica i generiranje klona T-stanica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10188893 | 2010-10-26 | ||
| PCT/EP2011/005400 WO2012055551A2 (de) | 2010-10-26 | 2011-10-26 | NFĸB-SIGNALWEG-MANIPULIERTE DENDRITISCHE ZELLEN |
| EP11787599.7A EP2633034B1 (de) | 2010-10-26 | 2011-10-26 | NFkB-SIGNALWEG-MANIPULIERTE DENDRITISCHE ZELLEN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180334T1 true HRP20180334T1 (hr) | 2018-04-06 |
Family
ID=43629060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180334TT HRP20180334T1 (hr) | 2010-10-26 | 2018-02-23 | DENDRITIČKE STANICE S MANIPULIRANIM SIGNALNIM PUTEM NFkB |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9862968B2 (hr) |
| EP (1) | EP2633034B1 (hr) |
| CY (1) | CY1119959T1 (hr) |
| DK (1) | DK2633034T3 (hr) |
| ES (1) | ES2661369T3 (hr) |
| HR (1) | HRP20180334T1 (hr) |
| HU (1) | HUE036148T2 (hr) |
| LT (1) | LT2633034T (hr) |
| NO (1) | NO2633034T3 (hr) |
| PL (1) | PL2633034T3 (hr) |
| PT (1) | PT2633034T (hr) |
| RS (1) | RS56923B1 (hr) |
| SI (1) | SI2633034T1 (hr) |
| TR (1) | TR201802790T4 (hr) |
| WO (1) | WO2012055551A2 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019008369A2 (pt) * | 2016-10-26 | 2019-10-01 | Modernatx Inc | ácidos ribonucleicos mensageiros para intensificar respostas imunes e métodos para uso dos mesmos |
| BR112019015797A2 (pt) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
| WO2019241666A1 (en) * | 2018-06-14 | 2019-12-19 | Thomas Jefferson University | Vaccine vector encoding mutated gnaq to treat uveal melanoma and cancers having mutated gnaq and gna11 proteins |
| CN117534753B (zh) * | 2023-12-07 | 2024-05-10 | 北京博奥森生物技术有限公司 | 一种诱导高性能NF-κB多克隆抗体多肽及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10162480A1 (de) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| US20050059634A1 (en) * | 2003-07-28 | 2005-03-17 | Venton Duane L. | Per-6-substituted-per-6-deoxy-cyclodextrins, and use of the same to inhibit soluble beta-amyloid-peptide derived oligomers and to treat alzheimer's and related diseases |
| JP2005304470A (ja) | 2004-03-26 | 2005-11-04 | Hisamitsu Pharmaceut Co Inc | アポトーシスを促進又は抑制する化合物をスクリーニングする方法、アポトーシス促進剤及びアポトーシス抑制剤 |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| US20090202492A1 (en) | 2008-01-25 | 2009-08-13 | University Of South Florida | Adenovirus vaccine utilizing ikk as adjuvant |
-
2011
- 2011-10-26 SI SI201131437T patent/SI2633034T1/en unknown
- 2011-10-26 EP EP11787599.7A patent/EP2633034B1/de active Active
- 2011-10-26 LT LTEP11787599.7T patent/LT2633034T/lt unknown
- 2011-10-26 ES ES11787599.7T patent/ES2661369T3/es active Active
- 2011-10-26 RS RS20180232A patent/RS56923B1/sr unknown
- 2011-10-26 US US13/881,592 patent/US9862968B2/en active Active
- 2011-10-26 HU HUE11787599A patent/HUE036148T2/hu unknown
- 2011-10-26 WO PCT/EP2011/005400 patent/WO2012055551A2/de active Application Filing
- 2011-10-26 PL PL11787599T patent/PL2633034T3/pl unknown
- 2011-10-26 NO NO11787599A patent/NO2633034T3/no unknown
- 2011-10-26 TR TR2018/02790T patent/TR201802790T4/tr unknown
- 2011-10-26 PT PT117875997T patent/PT2633034T/pt unknown
- 2011-10-26 DK DK11787599.7T patent/DK2633034T3/en active
-
2017
- 2017-12-04 US US15/830,225 patent/US11466289B2/en active Active
-
2018
- 2018-02-23 HR HRP20180334TT patent/HRP20180334T1/hr unknown
- 2018-02-27 CY CY20181100240T patent/CY1119959T1/el unknown
-
2022
- 2022-07-22 US US17/871,680 patent/US20230151384A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230151384A1 (en) | 2023-05-18 |
| EP2633034B1 (de) | 2017-11-29 |
| WO2012055551A2 (de) | 2012-05-03 |
| US20140004134A1 (en) | 2014-01-02 |
| EP2633034A2 (de) | 2013-09-04 |
| HUE036148T2 (hu) | 2018-06-28 |
| CY1119959T1 (el) | 2018-12-12 |
| PL2633034T3 (pl) | 2018-05-30 |
| RS56923B1 (sr) | 2018-05-31 |
| SI2633034T1 (en) | 2018-05-31 |
| NO2633034T3 (hr) | 2018-04-28 |
| DK2633034T3 (en) | 2018-03-05 |
| TR201802790T4 (tr) | 2018-03-21 |
| LT2633034T (lt) | 2018-03-26 |
| WO2012055551A3 (de) | 2012-07-19 |
| PT2633034T (pt) | 2018-03-05 |
| US20180230486A1 (en) | 2018-08-16 |
| US9862968B2 (en) | 2018-01-09 |
| ES2661369T3 (es) | 2018-03-28 |
| US11466289B2 (en) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180334T1 (hr) | DENDRITIČKE STANICE S MANIPULIRANIM SIGNALNIM PUTEM NFkB | |
| JP5816720B2 (ja) | Ｔｌｒ９の新規な合成アゴニスト | |
| CN103502439B (zh) | 用于抗原特异性t细胞增殖的方法 | |
| JP6010136B2 (ja) | ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物 | |
| Somamoto et al. | Antiviral functions of CD8+ cytotoxic T cells in teleost fish | |
| ES2643943T3 (es) | Potenciación de la capacidad de las células presentadoras de antígeno humanas para estimular células T tanto in vitro como in vivo y su uso en la vacunación | |
| KR101831713B1 (ko) | 공유결합적으로 폐쇄된 논-코딩 면역조절 dna 구조체 | |
| HK1103104A1 (en) | Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy | |
| Yang et al. | Preparation and antitumor effects of nanovaccines with MAGE-3 peptides in transplanted gastric cancer in mice | |
| JP6789913B2 (ja) | 能動免疫療法のためのＴｈ１ワクチン接種プライミング | |
| Zhao et al. | The immune responses of HLA-A* 0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI: C and R848 | |
| RU2016116708A (ru) | Олигопептиды металлопротеиназ и их терапевтическое применение | |
| Inoue et al. | Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides | |
| WO2019104353A1 (en) | Stimulator of interferon genes (sting) ligands and uses thereof | |
| ES2254527T3 (es) | Metodo para la preparacion de suspensiones de particulas submicronicas de agentes farmaceuticos. | |
| CN113493790A (zh) | 具有免疫调节功能的CpG ODN及其应用 | |
| Udey et al. | Skin dendritic cells in murine cutaneous leishmaniasis | |
| US20160279236A1 (en) | Use of rapamycin as vaccine adjuvant and preparation method therefor | |
| KR20160109356A (ko) | 자가 면역 질환 예방 또는 치료용 조성물 | |
| RU2013139439A (ru) | Олигопептиды металлопротеиназ и их терапевтическое применение | |
| CN109414023A (zh) | 用嵌合脊髓灰质炎病毒激活抗原呈递细胞的组合物和方法 | |
| Bae et al. | 812 Development of BCMA-targeted immunotherapy using vaccine-induced antigen-specific memory CD8+ T cells for treating patients with multiple myeloma | |
| WO2023211279A1 (en) | Adjuvant combinations for neopeptide vaccines | |
| Kupriyanov et al. | Pleiotropic functions of plasmacytoid dendritic cells in the pathogenesis of the rheumatoid arthritis | |
| US20120076827A1 (en) | Compositions and methods for generating an immune response in a subject |